Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:
“Breast cancer is entering a chemo-free, ADC-driven, ctDNA-guided era. ESMO Breast 2026 could quietly redefine practice. Here are 10 trials you should NOT miss.
1.PHERGain-2
- Early HER2+
- Chemo-free dual HER2 blockade strategy
- Can we safely omit chemo?
2.TRAIN-4
- Early HER2+
- Anthracycline-free ± escalation
- Is less more?
3.DESTINY-Breast11
- Neoadjuvant HER2+
- Trastuzumab deruxtecan vs standard
- ADC replacing chemo?
4.HER2CLIMB-02
- HER2+ metastatic
- Tucatinib + Trastuzumab emtansine
- Brain mets control
5.SATEEN
- Post-Trastuzumab deruxtecan setting
- Sequencing strategies
- What after T-DXd?
6.TROPION-Breast04
- HR+/HER2- metastatic
- Datopotamab deruxtecan
- Next ADC wave
7.DESTINY-Breast06 (updates)
- HER2-low / ultra-low
- Expanding Trastuzumab deruxtecan
- Redefining HER2 biology
8.PERSEVERE
- ctDNA-guided early BC
- MRD-based escalation/de-escalation
- Precision adjuvant therapy
9.lidERA (Giredestrant)
- Early ER+
- Giredestrant vs standard ET
- SERDs moving early
10.CAMBRIA-2
- ER+ high-risk
- Camizestrant
- Endocrine backbone changing?”
Janice Cowden, MBC Patient Advocate, shared Rishabh Jain’s post, adding:
“Top trials to watch at ESMO Breast 26, unless you’re looking for TNBC / mTNBC, apparently.
Thankfully, I collaborate with enough brilliant researchers to know there’s some really exciting research happening in TNBC. So I shared my ‘feelings’ w/ AI and asked it to make a graphic based on them. Because if we can’t be slightly snarky about the pace of progress, what else are we to do?”
Top 10 Breast Cancer Abstracts To Watch At ESMO Breast Cancer 2026
